Attorney Robert Rush joins Joe in Breckenridge to talk about challenging DEA scheduling decisions, from the 2024 DOI and DOC hearing to the emergency scheduling of 7-OH compounds and SR-17018. They also look at what FDA approval of MDMA and psilocybin could mean if only the pharmaceutical versions get rescheduled.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Psychedelics Today
PT 663 - Jackie Tileston - Penn Psychedelic Collaborative
PT 662 - Jordan Kronick - PEAKING
PT 661 - Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
PT 660 - Josh Lipson & Roman Palitsky: Psychedelic Harms and the Post-Psychedelic Challenges Study
Get summaries like this every morning.
Free AI-powered recaps of Psychedelics Today and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.